Watrous, Daniel

Watrous, Daniel was paid $5.01M by Medicaid between Jan 2018 and Nov 2024, across 25 billing codes. Its largest line is 96365, Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour — 21% of everything it billed.

33Billing provider infoWATROUS, DANIEL
VISALIA, CA 93291

33aNPI1841246568assigned 05/25/2006

33bProvider typeRheumatology Physician

28Total paid$5.01M

24GClaims69,279

24DCodes billed25

24AFirst – last monthJan 2018 – Nov 2024

Compared with peers

Next to other Rheumatology Physician providers in California

Rank by total paid#7 of 147

Median peer was paid$43K

This provider vs. median116×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	5,681	$395K
2019	7,283	$442K
2020	7,447	$393K
2021	9,695	$722K
2022	13,831	$1.06M
2023	13,933	$673K
2024incomplete	11,409	$1.32M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	21%	5,543	4,932	$1.07M
J0490	Injection, belimumab, 10 mg	14%	514	411	$689K
J1602	Injection, golimumab, 1 mg, for intravenous use	11%	900	885	$567K
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	10%	36,445	33,235	$524K
J3262	Injection, tocilizumab, 1 mg	9.7%	454	387	$487K
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	8.9%	2,832	2,436	$448K
J7050	Infusion, normal saline solution, 250 cc	5.8%	1,757	1,448	$291K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	4.9%	5,333	4,063	$245K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	3.3%	904	852	$164K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	2.6%	163	143	$132K
96415		2.1%	2,778	2,391	$105K
99204	Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	1.6%	4,737	4,698	$79K

13 more codes

Q5121	Injection, infliximab-axxq, biosimilar, (avsola), 10 mg	1.1%	184	$57K
96375	Therapeutic injection; each additional sequential IV push	1.1%	1,272	$54K
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	1,823	$33K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	<1%	54	$16K
J1040	Injection, methylprednisolone acetate, 80 mg	<1%	1,240	$15K
99213	Doctor's office visit, returning patient (routine)	<1%	661	$14K
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	839	$11K
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	<1%	14	$8K
J1010	Injection, methylprednisolone acetate, 1 mg	<1%	114	$793.62
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	219	$659.10
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	322	$647.93
J2919	Injection, methylprednisolone sodium succinate, 5 mg	<1%	162	$286.81
36415	Collection of venous blood by venipuncture	0%	15	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.